Sorafenib as adjuvant therapy following radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a multicenter analysis.

Authors:
Zhou Q; Wang X; Li R; Wang C; Wang J and 5 more

Journal:
J Gastroenterol

Publication Year: 2022

DOI:
10.1007/s00535-022-01895-3

PMCID:
PMC9392709

PMID:
35816221

Journal Information

Full Title: J Gastroenterol

Abbreviation: J Gastroenterol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Gastroenterology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Conflict of interestThe authors declare no conflicts of interest. Ethics statementThe Ethics Committee Board of the four hospitals approved this retrospective study and waived the requirement for patient consent for this retrospective review. Conflict of interest The authors declare no conflicts of interest."

Evidence found in paper:

"Funding This research was funded by the National Natural Science Foundation of China (No. 81627803, 91859201)."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025